Evidence map›Paper›PMID 32052314›Full record

SynthesisJournal of thrombosis and thrombolysis2020

DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.

V Mai, V F Tanguay, C A Guay, L Bertoletti, S Magnan, A F Turgeon, Y Lacasse, J C Lega, S Provencher

Abstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 4 pooled it
3.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

V MaiInstitut Universitaire de Cardiologie Et de Pneumologie de Québec Research Center, Laval University, Quebec, Canada.
V F TanguayInstitut Universitaire de Cardiologie Et de Pneumologie de Québec Research Center, Laval University, Quebec, Canada.
C A GuayInstitut Universitaire de Cardiologie Et de Pneumologie de Québec Research Center, Laval University, Quebec, Canada.
L BertolettiService de Médecine Vasculaire Et Thérapeutique, UMR 1059, SAINBIOSE and CIC 1408, CHU de St-Etienne, INSERM, St-Etienne, France.
S MagnanDepartment of Medicine, CHU de Québec, Université Laval, Quebec, QC, Canada.
A F TurgeonTrauma - Emergency - Critical Care Medicine, CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Université Laval, Quebec, QC, Canada.
Y LacasseInstitut Universitaire de Cardiologie Et de Pneumologie de Québec Research Center, Laval University, Quebec, Canada.
J C LegaUMR 5558, Laboratoire de Biométrie Et Biologie Evolutive, Groupe D'Etude Multidisciplinaire Des Maladies Thrombotiques (GEMMAT), Univ Lyon, CNRS, University of Lyon, 69003, Pierre-Bénite, France.
S ProvencherInstitut Universitaire de Cardiologie Et de Pneumologie de Québec Research Center, Laval University, Quebec, Canada. steeve.provencher@criucpq.ulaval.ca.
Institut universitaire de cardiologie et de pneumologie de Québec · CAUniversité Laval · CAInserm · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low molecular weight heparins (LMWH) are the standard of care for the treatment of cancer-associated venous thromboembolism (CA-VTE). We performed a systematic review and meta-analysis to compare the effects of direct oral anticoagulants (DOAC) versus LMWH for the treatment of CA-VTE. The primary efficacy and safety outcomes were VTE recurrence and major bleeding (MB). The secondary outcomes were clinically relevant non-MB (CRNMB), all-cause mortality and the net clinical benefit. We searched MEDLINE, EMBASE, CENTRAL and Web of Science (inception-December 2019) and abstracts of relevant conferences (2000-2019) to identify randomized controlled trials comparing DOAC and LMWH for the treatment of CA-VTE. Relative risks (RR) and 95% confidence intervals were estimated (Mantel-Haenszel method, random-effects models). A non-inferiority analysis with a margin of 1.3 for the upper boundary of the RR was conducted for the primary outcomes. From 637 references, we included four publications which encompass three trials (1756 patients). Compared to LMWH, DOAC were associated with a trend for decreased VTE recurrence (RR 0.51; 95%CI 0.25-1.03; p = 0.06; I

Indexed as

AnticoagulantsFactor Xa InhibitorsHemorrhageHeparin, Low-Molecular-WeightHumansNeoplasmsRecurrenceSecondary PreventionTreatment OutcomeVenous ThromboembolismAnticoagulantsFactor Xa InhibitorsHeparin, Low-Molecular-WeightBleedingCancerDirect oral anticoagulantLow molecular weight heparinVenous thromboembolism

Identifiers

PMID32052314
OpenAlexW3005776001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.